Efficacy

Efficacy of Riluzole (Glentek/Riluzol) in Amyotrophic Lateral Sclerosis (ALS)

Riluzole, marketed under brand names such as Glentek and Riluzol, is a medication that has been approved by regulatory agencies for the treatment of Amyotrophic Lateral Sclerosis (ALS). The efficacy of riluzole in ALS has been demonstrated in multiple clinical trials. It is believed to work by reducing the release of glutamate, which is thought to be involved in the death of neurons in patients with ALS. Studies have shown that riluzole can extend survival in ALS patients by several months, particularly in those with bulbar onset disease. Additionally, riluzole may delay the need for tracheostomy and mechanical ventilation, which are significant considerations in the management of ALS.

While riluzole does not halt the progression of ALS or reverse the damage already done, its efficacy in extending survival and delaying major milestones of disease progression provides a meaningful benefit in this progressive and fatal neurodegenerative disorder. The medication is generally well-tolerated, with the most common side effects being asthenia, nausea, and elevated liver enzymes. It is important to note that riluzole is not a cure for ALS, but it is currently one of the few treatments available that has a proven impact on the disease course.

Efficacy of Ibudilast (Ketas) in Amyotrophic Lateral Sclerosis (ALS)

Ibudilast, sold under the brand name Ketas among others, is a phosphodiesterase inhibitor with neuroprotective and anti-inflammatory properties. While it is not approved for the treatment of ALS in many countries, it has been the subject of research to determine its efficacy in this condition. Ibudilast's mechanism of action suggests potential benefits in ALS due to its ability to modulate the immune response and protect neurons from damage.

Clinical trials investigating ibudilast for ALS are less extensive than those for riluzole, and the evidence for its efficacy is still emerging. Some studies have indicated that ibudilast may have a favorable impact on the progression of ALS, but larger, well-designed clinical trials are needed to confirm these findings. As of the current knowledge cutoff, ibudilast is considered an experimental treatment for ALS, and its use is generally limited to clinical trials. Patients and healthcare providers are encouraged to consider the potential risks and benefits of ibudilast within the context of clinical studies.